Profile data is unavailable for this security.
About the company
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.72m
- Incorporated2007
- Employees67.00
- LocationCizzle Biotechnology Holdings PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 207 469 0930
- Fax+44 238 123 0382
- Websitehttps://cizzlebiotechnology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IXICO PLC | 6.00m | -1.87m | 3.38m | 89.00 | -- | 0.3372 | -- | 0.5641 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.58m | 50.00 | -- | 1.53 | -- | 2.26 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| Amur Minerals Corporation | 0.00 | -1.88m | 3.76m | 4.00 | -- | 0.309 | -- | -- | -0.2157 | -0.8706 | 0.00 | 0.3719 | 0.00 | -- | -- | 0.00 | -14.26 | -8.67 | -14.89 | -9.02 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | 8.21 | -- | -- | -- |
| ValiRx Plc | 9.60k | -2.04m | 3.90m | 8.00 | -- | 0.9378 | -- | 406.70 | -0.0201 | -0.0201 | 0.00009 | 0.0315 | 0.0027 | -- | 0.0682 | -- | -59.88 | -50.57 | -58.27 | -54.77 | 85.00 | -- | -22,164.48 | -103,908.50 | 2.32 | -520.03 | 0.0075 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 4.91m | 4.00 | -- | 1.01 | -- | 379.33 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 6.64m | 67.00 | -- | 4.04 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| ImmuPharma PLC | 69.96k | -2.99m | 8.93m | 13.00 | -- | 4.12 | -- | 127.68 | -0.0092 | -0.0092 | 0.0002 | 0.0052 | 0.0227 | -- | 0.1706 | 5,381.54 | -97.05 | -89.69 | -159.35 | -106.57 | -- | -- | -4,275.31 | -7,958.69 | -- | -2.40 | 0.00 | -- | -100.00 | -- | 53.42 | -- | 32.98 | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.33m | 9.49m | 10.00 | -- | 2.68 | -- | -- | -0.0352 | -0.0352 | 0.00 | 0.0428 | 0.00 | -- | -- | 0.00 | -50.56 | -- | -57.49 | -- | -- | -- | -- | -- | -- | -- | 0.1267 | -- | -- | -- | -6.71 | -- | -- | -- |
| Kanabo Group PLC | 895.00k | -7.99m | 9.80m | 20.00 | -- | 1.30 | -- | 10.95 | -0.0137 | -0.0137 | 0.0017 | 0.0119 | 0.0785 | 11.11 | 28.41 | -- | -70.12 | -75.83 | -77.61 | -83.33 | 14.97 | -- | -893.30 | -1,267.35 | 4.96 | -10.43 | 0.035 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 9.87m | 91.00 | -- | 1.06 | -- | 1.09 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
Data as of May 31 2024. Currency figures normalised to Cizzle Biotechnology Holdings PLC's reporting currency: UK Pound GBX
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Unicorn Asset Management Ltd.as of 30 Apr 2024 | 34.20k | 0.01% |
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
